These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 27167113

  • 21. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.
    Jiang L, Ye L, Ma L, Ren Y, Zhou X, Mei C, Xu G, Yang H, Lu C, Luo Y, Zhu S, Wang L, Shen C, Yang W, Zhang Q, Wang Y, Lang W, Han Y, Jin J, Tong H.
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):845-856. PubMed ID: 35013795
    [Abstract] [Full Text] [Related]

  • 22. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
    Svobodova K, Zemanova Z, Lhotska H, Novakova M, Podskalska L, Belickova M, Brezinova J, Sarova I, Izakova S, Lizcova L, Berkova A, Siskova M, Jonasova A, Cermak J, Michalova K.
    Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
    [Abstract] [Full Text] [Related]

  • 23. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
    Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J.
    Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.
    McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF.
    Oncotarget; 2015 Oct 27; 6(33):34437-45. PubMed ID: 26416416
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SA.
    J Hematol Oncol; 2015 May 08; 8():45. PubMed ID: 25952993
    [Abstract] [Full Text] [Related]

  • 30. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
    Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.
    Haematologica; 2013 Dec 08; 98(12):1856-64. PubMed ID: 23831921
    [Abstract] [Full Text] [Related]

  • 31. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
    Loghavi S, Al-Ibraheemi A, Zuo Z, Garcia-Manero G, Yabe M, Wang SA, Kantarjian HM, Yin CC, Miranda RN, Luthra R, Medeiros LJ, Bueso-Ramos CE, Khoury JD.
    Br J Haematol; 2015 Oct 08; 171(1):91-9. PubMed ID: 26123119
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
    Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.
    Haematologica; 2018 Apr 08; 103(4):e143-e146. PubMed ID: 29269520
    [No Abstract] [Full Text] [Related]

  • 34. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E, Weber UM, Gore S.
    Expert Rev Hematol; 2020 Mar 08; 13(3):233-239. PubMed ID: 32067540
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D, Bühler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Döhner H, Stilgenbauer S.
    J Clin Oncol; 2010 Oct 10; 28(29):4473-9. PubMed ID: 20697090
    [Abstract] [Full Text] [Related]

  • 37. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.
    Oncotarget; 2015 Apr 10; 6(10):8388-96. PubMed ID: 25860933
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
    Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.
    Haematologica; 2017 Mar 10; 102(3):498-508. PubMed ID: 27884971
    [Abstract] [Full Text] [Related]

  • 40. [Effect of TP53 Allelic State on Clinical Performance and Prognosis of Patients with Myelodysplastic Syndrome].
    Shen K, Hu DY, Chen SN.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Jun 10; 32(3):811-818. PubMed ID: 38926972
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.